AllSci News
Outlook Therapeutics to resubmit Lytenava BLA for wAMD after FDA appeal win
Outlook Therapeutics (Nasdaq: OTLK), based in Iselin, New Jersey, plans to resubmit a Biologics License Application (BLA) to the US FDA for Lytenava...
FDA delays decision on AstraZeneca's camizestrant after ODAC reverse
AstraZeneca (LSE/STO/NYSE: AZN) has disclosed that the US FDA has extended the Prescription Drug User Fee Act (PDUFA) date for the New Drug Application...
Parabilis seeks Nasdaq listing with USD 75m strategic investment from Regeneron
Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company whose lead oncology asset has generated a 74% objective response rate in...
Biomunex partners with Gordion Bioscience and Tangramed Biotech on AI-driven target discovery
Biomunex Pharmaceuticals, a Paris and Cambridge, Massachusetts-based biopharmaceutical company focused on bispecific and multi-specific antibody immunotherapies, has announced two separate research collaborations…
Pierre Fabre receives CHMP positive opinion for Braftovi in first-line BRAF V600E-mutant colorectal cancer
Pierre Fabre receives CHMP positive opinion for Braftovi in first-line BRAF V600E-mutant colorectal cancer
Aphios picks up US patent for Bryoid B14B marine-derived composition targeting Alzheimer’s and cancer
Aphios Corporation (North Reading, Massachusetts) has received a notice of allowance from the US Patent and Trademark Office for a divisional patent…
Merz finds China partner for Inbrija in Kvvit
Merz Therapeutics GmbH and China-based Jiangxi Kvvit Pharmaceutical Co., Ltd, announced an exclusive license and collaboration agreement covering Inbrija (levodopa inhalation powder)…
Insilico, Human Longevity partner on AI foundation models for longevity science
Insilico Medicine (HKEX: 3696) and Human Life Foundation Models, Inc. (HLFM), a newly established entity created by Human Longevity, Inc., announced a…
TransThera, Allist to test out AXL/FLT3 inhibitor with EGFRi against NSCLC
TransThera Sciences (Nanjing), Inc. (HKEX: 2617) and Shanghai Allist Pharmaceuticals Co., Ltd. (SSE: 688578) have entered a clinical trial collaboration and...
Incyte expands molecular AI collaboration with Genesis in USD 1b+ deal
Incyte (Nasdaq: INCY) has expanded its molecular AI collaboration with Genesis Molecular AI, committing USD 120 million upfront to broaden deployment of...
Adcendo and MSD partner to pair TF-targeting ADC with Keytruda
Adcendo ApS, a Copenhagen-based clinical-stage biotech, and MSD (Merck & Co., Rahway, NJ) announced a clinical trial collaboration and supply agreement to…
Autobahn’s CNS thyroid hormone receptor agonist earns FDA Fast Track designation for bipolar depression
Autobahn Therapeutics, a San Diego-based biotechnology company, announced receipt of US FDA Fast Track Designation for elunetirom (ABX-002), an oral, once-daily, brain-penetrant…
Dyne files z-rostudirsen for US approval in exon 51 DMD
Dyne Therapeutics (Nasdaq: DYN), based in Waltham, Massachusetts, has submitted a Biologics License Application (BLA) to the US FDA for zeleciment...
EU recommends AZ, Daiichi's Enhertu for HER2 tumor-agnostic indication expansion
AstraZeneca (LSE/STO/NYSE: AZN) and Daiichi Sankyo have received a positive opinion from the European Medicines Agency's Committee for Medicinal Products...
Lilly pushes into vaccines via USD 3.8b in three separate acquisitions
Eli Lilly (NYSE: LLY) has announced agreements to acquire three private companies — Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. — in...
The AllSci Brief
Systematic R&D and deal news. Daily.